S.E.C. Asks Amgen About Anemia Drug
600427
Amgen received an informal inquiry from the S.E.C. seeking more information about a Danish study of the companyâs Aranesp anemia drug.
44172
Biotech giant Inc. Amgen and the pharmaceuticals division of health-care products company Wyeth said Tuesday the Food and Drug Administration approved their arthritis treatment Enbrel to induce a major clinical
453423
U.S. cancer doctors on Thursday plan  to ratchet up pressure on the federal Medicare agency to  reverse new limits on use of anemia drugs made by Amgen Inc.  and Johnson & Johnson.
169384
The US Food and Drug Administration is pushing for an expanded review of MDS Pharma&#39;s generic drug studies at its Montreal laboratories, and has requested a meeting with the company to discuss its concerns.
348744
Amgen has said that its experimental drug for osteoporosis increased bone density in women at least as well in a clinical trial as the widely prescribed Fosamax medicine from Merck.
512456
NEW YORK, September 9 (New Ratings) - The FDA has raised questions regarding AstraZenecaâs (AZN.NYS) blood thinner, Exanta. The leading pharmaceutical companyâs hopes had been pinned on Exanta, which
386658
The U.S. Food and Drug Administration is facing new questions about its ability to police the safety of medicines after they reach the market following concerns about a widely used diabetes drug.
692137
Amgen announces data from its top pipeline drug candidate.
283701
GlaxoSmithKline said on Monday that U.S.  regulators were seeking further information prior to the  possible approval of cervical cancer vaccine Cervarix.
97646
The Motley Fool - As investors waited anxiously for Amgen's (Nasdaq: AMGN - News) earnings report, the United Kingdom's high court snuck in with a stinker. It ruled that Transkaryotic Therapies (Nasdaq: TKTX - News) and Sanofi-Aventis (NYSE: SNYT - News) did not infringe on the patent for EPO, Amgen's anemia treatment (which accounts for 27% of its sales), and ruled the patent invalid.
232138
MGI Pharma Inc. MOGN.O will spend up  to $85 million for a stake in SuperGen Inc. SUPG.O and global  rights to develop and sell SuperGen's experimental drug for an  often-fatal cancer of the bone marrow, the companies said on  Wednesday.
547870
A panel of experts advising the Food and Drug Administration gave strong signals yesterday that it thinks the blockbuster anemia drug called erythropoietin is overused in cancer treatment and may, in fact, be shortening the lives of some patients who take it.
95222
Alkermes Inc. said the Securities and Exchange Commission has asked for information on accounting for its marketing partnership for a treatment for alcoholism.
457661
U.S. regulators need more clinical trials before they can approve heart-scan contrast agent MS-325 from Germany's Schering and U.S. partner Epix Pharmaceuticals, the companies said on Friday.
661853
Ford, as well as G.M. and Delphi, also said they had been asked to provide the S.E.C. with information regarding practices related to pension and healthcare expenses.
703630
U.S. Food and Drug Administration staff reviewers on Tuesday questioned clinical data for non-Hodgkin's lymphoma drug Marqibo, made by Inex Pharmaceuticals Corp. and Enzon Pharmaceuticals Inc..
500050
Debate about the safety of a group of  anemia drugs widely used in cancer patients should focus on a  minority of patients who got the drugs for unapproved uses,  doctors said on Sunday.